BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
19.7% of Nutriband shares are held by institutional investors. 54.1% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares BioNxt Solutions and Nutriband”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioNxt Solutions | $20,000.00 | 3,420.13 | -$3.88 million | ($0.04) | -14.77 |
| Nutriband | $2.14 million | 40.19 | -$10.48 million | ($2.87) | -2.49 |
BioNxt Solutions has higher earnings, but lower revenue than Nutriband. BioNxt Solutions is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
BioNxt Solutions has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
Profitability
This table compares BioNxt Solutions and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioNxt Solutions | -19,165.00% | N/A | -815.86% |
| Nutriband | -398.29% | -85.40% | -73.45% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for BioNxt Solutions and Nutriband, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioNxt Solutions | 0 | 0 | 0 | 0 | 0.00 |
| Nutriband | 0 | 0 | 1 | 0 | 3.00 |
Nutriband has a consensus target price of $13.00, suggesting a potential upside of 81.82%. Given Nutriband’s stronger consensus rating and higher probable upside, analysts clearly believe Nutriband is more favorable than BioNxt Solutions.
Summary
Nutriband beats BioNxt Solutions on 10 of the 14 factors compared between the two stocks.
About BioNxt Solutions
BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for BioNxt Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNxt Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
